Clinical Trial Update: A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension [Phase 2]

View source ↗

Summary

Phase 2 study assessing dose-response of HCP1803 in patients with essential hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• HCP1803

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hypertension | Phase 2 | Status: COMPLETED